Zhenduanxue lilun yu shijian (Feb 2021)

Eleven cases of dermatomyositis accompanied with gynecological malignant tumor: clinical characteristics and short-term follow-up

  • LIU Chang, CAO Hua, FENG Weiwei, SHEN Lifei

DOI
https://doi.org/10.16150/j.1671-2870.2021.01.008
Journal volume & issue
Vol. 20, no. 01
pp. 53 – 59

Abstract

Read online

Objective: To analyze the clinical characteristics, diagnosis and treatment of dermatomyositis (DM) accompanied with gynecological malignant tumor to provide evidence for early detection and intervention of the disease. Methods: The clinical data of 11 DM patients with gynecological malignant tumor treated in our hospital from 2015 to 2020 were enrolled, and the clinical characteristics and treatment protocols were analyzed. Results: In eleven patients diagnosed DM accompanied with gynecological malignant tumor, three types of cancer were identified, including endometrial cancer (4/11), cervical cancer (2/11), and ovarian cancer (5/11). Eightout of 11 patients were diagnosed stage Ⅲ-Ⅳ gynecological cancer according to 2020 FIGO(International Federation of Gynecology and Obstetrics) gynecological tumor staging. Ten patients were screened for gynecological cancer by imaging and tumor biomarkers,and diagnosed gynecological cancer after being confirmed as DM 1 week to 21 months. The other one patient was found to have ovarian cancer at 21st month after diagnosis of DM because of the increased level of CA12-5 (carbohydrate antigen12-5) during the follow-up, however, her CT imaging of the pelvic and abdominal cavity and tumor biomarkers were normal in initial screening. The anti-TIF1-γ antibodies in 8 DM patients were tested, and 6 of them were positive. Except one patient with cervical cancer receiving directly radical radiotherapy and chemotherapy, the other 10 patients received gynecological tumor resection. The overall survival rate was 100% during the follow-up of 2 months to 2 years. There was no tumor recurrence duringthe follow-up, but the DM recurrence appeared in 2patients. Conclusions: For the DM patients lacking signs of malignant tumor in the initial screening, the continuing follow-upand screening for tumor biomarkers should get more attention.The DM patients accompanied gynecological malignant tumor often showed late-stage cancer (Ⅲ-Ⅳ staging) and the treatment should be mainly focused on the gynecological tumor.

Keywords